Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11491376 | 1.00 | MAPT (0.67) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL16294284 | 0.94 | MAPT (0.59) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL21952141 | 0.94 | MAPT (0.59) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL31378279 | 0.94 | MAPT (0.59) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL16294268 | 0.94 | MAPT (0.59) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL16295173 | 0.94 | MAPT (0.59) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL16295174 | 0.94 | MAPT (0.59) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL29626505 | 0.91 | HCAR2 (0.57) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL5026120 | 0.87 | HCAR2 (0.52) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL5026118 | 0.87 | HCAR2 (0.52) | MAPTHCAR2KEAP1NFE2L2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118806759-A | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-10-22 | — | — | CN | claimed |
| CN-115867260-B | Systemic formulations of pyridone derivatives for celiac disease | 福尔克博士药物有限责任公司 | 2024-10-01 | — | — | CN | claimed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | claimed |
| CN-115715187-B | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-07-19 | — | — | CN | claimed |
| CN-118234489-A | Oral formulations of pyridone derivatives and their use in the prevention and/or treatment of intestinal fibrosis | 福尔克博士药物有限责任公司 | 2024-06-21 | — | — | CN | claimed |
| CN-118806759-A | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118806759-A | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-115867260-B | Systemic formulations of pyridone derivatives for celiac disease | 福尔克博士药物有限责任公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-115715187-B | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-115715187-B | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118234489-A | Oral formulations of pyridone derivatives and their use in the prevention and/or treatment of intestinal fibrosis | 福尔克博士药物有限责任公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-115867260-A | Systemic formulations of pyridone derivatives for celiac disease | 福尔克博士药物有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115715187-A | Systemic formulations of pyridone derivatives for TG 2-related diseases | 福尔克博士药物有限责任公司 | 2023-02-24 | — | — | CN | disclosed |
| US-4315032-A | ANTITHROMBOGENIC AGENTS, ANTIULCER AGENTS | TEITIN LIMITED (JP) | 1982-02-09 | — | — | US | disclosed |
| EP-0019475-A2 | Process for preparing adjacently disubstituted ketones, novel prostaglandins E1 and anti-thrombotic compositions containing them | TEIJIN LIMITED (JP) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MAPT 989/4885HCAR2 2965/4885KEAP1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.